###begin article-title 0
Dynamic and redundant regulation of LRRK2 and LRRK1 expression
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 21 50 21 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">leucine-rich repeat kinase 2 </italic>
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 481 487 <span type="species:ncbi:10090">murine</span>
Mutations within the leucine-rich repeat kinase 2 (LRRK2) gene account for a significant proportion of autosomal-dominant and some late-onset sporadic Parkinson's disease. Elucidation of LRRK2 protein function in health and disease provides an opportunity for deciphering molecular pathways important in neurodegeneration. In mammals, LRRK1 and LRRK2 protein comprise a unique family encoding a GTPase domain that controls intrinsic kinase activity. The expression profiles of the murine LRRK proteins have not been fully described and insufficiently characterized antibodies have produced conflicting results in the literature.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 114 120 114 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 525 531 525 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 547 553 547 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
###xml 124 129 <span type="species:ncbi:9606">human</span>
###xml 181 186 <span type="species:ncbi:10090">mouse</span>
###xml 205 210 <span type="species:ncbi:9606">human</span>
###xml 266 271 <span type="species:ncbi:9606">human</span>
###xml 318 323 <span type="species:ncbi:9606">human</span>
###xml 384 389 <span type="species:ncbi:10090">mouse</span>
###xml 433 438 <span type="species:ncbi:10090">mouse</span>
Herein, we comprehensively evaluate twenty-one commercially available antibodies to the LRRK2 protein using mouse LRRK2 and human LRRK2 expression vectors, wild-type and LRRK2-null mouse brain lysates and human brain lysates. Eleven antibodies detect over-expressed human LRRK2 while four antibodies detect endogenous human LRRK2. In contrast, two antibodies recognize over-expressed mouse LRRK2 and one antibody detected endogenous mouse LRRK2. LRRK2 protein resides in both soluble and detergent soluble protein fractions. LRRK2 and the related LRRK1 genes encode low levels of expressed mRNA species corresponding to low levels of protein both during development and in adulthood with largely redundant expression profiles.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 561 567 561 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 571 576 571 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 111 116 <span type="species:ncbi:10090">mouse</span>
###xml 204 209 <span type="species:ncbi:10090">mouse</span>
###xml 305 310 <span type="species:ncbi:9606">human</span>
###xml 392 397 <span type="species:ncbi:9606">human</span>
Despite previously published results, commercially available antibodies generally fail to recognize endogenous mouse LRRK2 protein; however, several antibodies retain the ability to detect over-expressed mouse LRRK2 protein. Over half of the commercially available antibodies tested detect over-expressed human LRRK2 protein and some have sufficient specificity to detect endogenous LRRK2 in human brain. The mammalian LRRK proteins are developmentally regulated in several tissues and coordinated expression suggest possible redundancy in the function between LRRK1 and LRRK2.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 17 46 17 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">leucine-rich repeat kinase 2 </italic>
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 378 379 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 399 405 399 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 693 699 693 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 870 872 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
Mutations in the leucine-rich repeat kinase 2 (LRRK2, OMIM 609007) gene are the most common known cause for sporadic and familial Parkinson's Disease (PD) [1-4]. The most frequent mutation in North America and Europe is a glycine to serine substitution at residue 2019 (G2019S) in the LRRK2 protein which accounts for up to 10% in familial cases and up to 2% in sporadic cases [5-9]. Frequencies of LRRK2 mutations in PD cases are reported as high as 40% in North Africans and Ashkenazi Jews [10,11], but since penetrance of the mutation in 80 year old carriers may be as low as 30% with standard diagnosis [12] the discrimination between familial and sporadic disease becomes difficult [13]. LRRK2 mutation carriers present with similar clinical and neurochemical features to sporadic disease, and with only few exceptions, present with typical Lewy body pathology [14,15].
###end p 9
###begin p 10
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 135 140 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 150 156 150 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 335 341 335 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 347 348 347 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 394 400 394 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 404 409 404 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 791 797 791 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 801 806 801 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1</italic>
Due to the unprecedented frequency of mutations in LRRK2 occurring in PD, a number of laboratories have embarked on the development of LRRK2-null and LRRK2 transgenic animals. In multiple-tissue Northern blots, LRRK2 is nearly constitutively expressed but the timing of expression has not been described nor the profile of the related LRRK1 gene [1,2,16]. Given the sequence similarity between LRRK1 and LRRK2, a complete expression profile may indicate whether redundancy in function could mask a phenotype in transgenic and knock-out animals. In addition, inappropriate expression in transgenic animals due to off-tissue expression or abnormal developmental expression may initiate undesirable phenotypes and reduce the utility as a PD model. To provide the complete expression profile of LRRK2 and LRRK1, we utilize quantitative PCR, Northern blot and Western blot experiments to track levels of expression.
###end p 10
###begin p 11
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 143 148 <span type="species:ncbi:9606">human</span>
###xml 335 340 <span type="species:ncbi:9606">human</span>
###xml 494 499 <span type="species:ncbi:10090">mouse</span>
###xml 504 509 <span type="species:ncbi:9606">human</span>
The 2527 amino acid multi-domain protein kinase LRRK2 is associated with membranes in rodent brain and is present in tissues relevant to PD in human and rodent brain [17-20]. Some studies suggest the presence of LRRK2 protein in disease-associated aggregations such as Lewy bodies and Lewy neurites, using different antibodies against human LRRK2 [21-23]. To aid the neurodegeneration research community we present a detailed characterization of twenty-one commercially available antibodies to mouse and human LRRK2 purported as specific to the 280 kDa protein.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
LRRK2 is present in both freely soluble and SDS-soluble fractions of mouse brain lysate as determined by antibody JH5514
###end title 13
###begin p 14
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 593 594 593 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 820 826 820 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 842 844 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 967 969 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 114 119 <span type="species:ncbi:9606">human</span>
###xml 188 193 <span type="species:ncbi:10090">mouse</span>
###xml 197 202 <span type="species:ncbi:9606">human</span>
###xml 280 285 <span type="species:ncbi:10090">mouse</span>
###xml 441 445 <span type="species:ncbi:10090">mice</span>
###xml 466 470 <span type="species:ncbi:10090">mice</span>
###xml 653 658 <span type="species:ncbi:9606">human</span>
###xml 706 711 <span type="species:ncbi:10090">mouse</span>
###xml 716 722 <span type="species:ncbi:9606">humans</span>
###xml 829 833 <span type="species:ncbi:10090">mice</span>
###xml 1174 1179 <span type="species:ncbi:9606">human</span>
###xml 1215 1220 <span type="species:ncbi:9606">human</span>
###xml 1252 1257 <span type="species:ncbi:9606">human</span>
###xml 1294 1297 <span type="species:ncbi:10116">rat</span>
Published literature to date suggests many commercially available antibodies raised against peptides derived from human LRRK2 sequence detect a protein of approximately 280 kDa in size in mouse or human tissue and/or cell lines [21-28]. To confirm whether these antibodies detect mouse LRRK2 or cross-reactive protein species unrelated to LRRK2 migrating near 280 kDa, we performed immunoblot analyses of the various antibodies in wild type mice and LRRK2 knock-out mice in which exons 39 and 40 are disrupted (S. Biskup, M. Sasaski, V.L. Dawson and T.M. Dawson, personal observation) (Figure 1). Our previously characterized antibody JH5514 recognizes human over-expressed and endogenous LRRK2 protein in mouse and humans with minimal cross-reactivity with other protein species and LRRK2 immunoreactivity is absent in LRRK2 KO mice (Figure 1A). No endogenous LRRK2 can be detected in HEK-293T cells even with long exposures and high antibody concentrations (Figure 1A and data not shown). Our validated antibody JH5514 does not detect a protein of the appropriate size, determined through alignment with recombinant LRRK2 protein, in any tested cell line lysate including human embryonic kidney (HEK-293T) cells, human neuroblastoma (SH-SY5Y) cells, human neuroblastoma (BE(2)-M17) cells and rat adrenal (PC-12) cells (data not shown). Several of these cell lines, including HEK-293T and SH-SY5Y express a low level of LRRK2 mRNA compared with brain tissue suggesting post-transcriptional regulation (data not shown).
###end p 14
###begin p 15
###xml 0 85 0 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Biochemical characterization of LRRK2 and testing of LRRK2 antibodies on mouse tissue</bold>
###xml 1166 1171 1166 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
###xml 105 110 <span type="species:ncbi:10090">mouse</span>
###xml 190 195 <span type="species:ncbi:10090">mouse</span>
###xml 481 486 <span type="species:ncbi:10090">mouse</span>
###xml 1129 1134 <span type="species:ncbi:10090">mouse</span>
###xml 1182 1187 <span type="species:ncbi:10090">mouse</span>
Biochemical characterization of LRRK2 and testing of LRRK2 antibodies on mouse tissue. A) Over-expressed mouse LRRK2 detected by JH5514 versus empty vector transfected HEK-293T cells. Whole mouse brain was mechanically homogenized in either PBS (low salt buffer), high salt buffer (PBS supplemented to 600 mM NaCl), 1% Triton X-100 (in PBS), 1% SDS (in PBS) or RIPA (1% SDS, 1% sodium deoxycholate, 1% NP-40). All buffers contained complete protease inhibitors (Roche). A knockout mouse brain is homogenized in PBS (low salt) alone and shown as control. B) Lysates derived from HEK-293T cells transfected with mLRRK2 plasmids were incubated in 1 x Laemmli sample buffer at the indicated temperatures for 10 minutes and then analyzed by SDS-PAGE. Plasticware used to process the protein samples were either siliconized or left untreated. Indicated samples were supplemented with 5% Formic acid (FA) or 4M urea after 10 minute incubation at the indicated temperature. C) LRRK2 antibodies Novus 267 and 268, Abgent AP7099b, and Chemicon (AB9682) in addition to Alexis (AT106) and Cell Signaling (2567) were tested on over-expressed mouse LRRK2 protein and wildtype and LRRK2-deficient mouse brain homogenized in PBS alone. All antibodies recognize cross-reactive bands near the expected size of LRRK2. An arrow denotes the position of LRRK2 in the Alexis (AT106) blot. All antibodies were tested on at least two independent membranes and lysates using optimized exposure conditions with similar results.
###end p 15
###begin p 16
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1090 1092 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
###xml 285 290 <span type="species:ncbi:10090">mouse</span>
###xml 347 352 <span type="species:ncbi:10090">Mouse</span>
With a series of different extraction buffers for mouse brain using LRRK2-null brain tissue as a control, we show that membrane disruption through simple mechanical homogenization of brain tissue in PBS (low salt buffer) or in high salt buffer is sufficient to extract the majority of mouse LRRK2 that can be detected by Western Blot (Figure 1A). Mouse LRRK2 protein is also detected in relatively insoluble fractions only resolved through the addition of 1% SDS buffer. Incubation of lysate samples supplemented with 1x Laemmli sample buffer for ten minutes at temperatures above room temperature led to a loss of recoverable levels of LRRK2 (Figure 1B). This phenomenon is apparently not due to an interaction with plastic disposables since siliconized tubes and tips had no effect. Supplementation of the sample buffer lysate solution with either 4 M urea or 5% Formic acid (FA) after incubation for ten minutes at 90degreesC resulted in a significant recovery of LRRK2 protein levels, suggesting that LRRK2 may form SDS-resistant insoluble aggregates with elevated temperatures (Figure 1B).
###end p 16
###begin title 17
###xml 79 84 <span type="species:ncbi:10090">mouse</span>
Commercially available antibodies that recognize over-expressed and endogenous mouse LRRK2
###end title 17
###begin p 18
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mLRRK2</italic>
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 379 380 379 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 880 885 880 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 1073 1078 1073 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 1302 1304 1302 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 1360 1367 1360 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mLRRK2 </italic>
###xml 32 37 <span type="species:ncbi:10090">mouse</span>
###xml 148 153 <span type="species:ncbi:10090">mouse</span>
###xml 674 679 <span type="species:ncbi:10090">mouse</span>
###xml 684 689 <span type="species:ncbi:9606">human</span>
Using a panel of over-expressed mouse LRRK2 (mLRRK2) versus empty vector transfected HEK-293T cells in combination with LRRK2-null versus wild-type mouse brain tissue, we tested twenty-one commercially available LRRK2 antibodies to determine specificity. Most of the antibodies cannot detect over-expressed mLRRK2 or endogenous wild-type mLRRK2 protein (For a summary, see Table 1). For example, the antibodies Novus 267, Novus 268, Abgent AP7099b do not have the sufficient specificity to detect mLRRK2, either over-expressed or endogenous using standard blotting conditions (Figure 1C). Of note, antibody AP7099b from Abgent was raised against a peptide identical between mouse and human. Typical for the majority of antibodies tested here, cross-reactive species near the molecular weight of LRRK2 protein confound the interpretation of blots when appropriate controls such as LRRK2-null brain lysate are not included. With very high concentrations and exposure times, many cross reactive bands appear near the expected size of LRRK2 protein but none are changed in the LRRK2-null brain lysate for all commercially available antibodies with the exception of the Alexis (AT106) antibody, which recognizes a faint band immediately under a prominent cross-reactive protein species near 280 kDa (Figure 1C). Other antibodies capable of detecting over-expressed mLRRK2 in HEK 293T cells such as the Cell Signaling (2567) and Chemicon (ab9682) antibodies recognize cross-reactive protein species that presumably mask endogenous mLRRK2 protein due to the insufficient separation afforded by commercially available gradient mini-gels.
###end p 18
###begin p 19
Summary of antibodies tested on Western Blot
###end p 19
###begin p 20
###xml 295 300 <span type="species:ncbi:9606">human</span>
Summary of the results of commercially available antibodies against LRRK2 tested on Western Blot. A (+) denotes antibodies that produce a discernable band specific to LRRK2 protein. A (-) denotes antibodies unable to detect a band specific to LRRK2 protein. Antibodies were designed against the human sequence unless otherwise indicated.
###end p 20
###begin title 21
###xml 79 84 <span type="species:ncbi:9606">human</span>
Commercially available antibodies that recognize over-expressed and endogenous human LRRK2
###end title 21
###begin p 22
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 568 576 568 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In situ </italic>
###xml 628 634 628 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 776 778 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 779 781 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 782 784 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1001 1003 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1094 1096 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 204 209 <span type="species:ncbi:9606">human</span>
###xml 386 391 <span type="species:ncbi:9606">human</span>
###xml 491 496 <span type="species:ncbi:9606">human</span>
###xml 547 552 <span type="species:ncbi:9606">human</span>
###xml 862 867 <span type="species:ncbi:9606">human</span>
All antibodies were additionally tested on human over-expressed LRRK2 versus empty vector transfected HEK-293T cells (Table 1). Figure 2A shows the panel of antibodies capable of detecting over-expressed human LRRK2 (Novus 267, Novus 268, Abgent AP7099e, AP7099f, AP7099g, AP7099h, Abcam 27482 and Cell Signaling 2567). We tested antibodies capable of robustly detecting over-expressed human LRRK2 protein (Novus 267, Novus 268, Abgent AP7099e, AP7099f, AP7099g, AP7099h, Abcam 27482) using human brain lysate derived from fresh-frozen samples of human temporal lobe. In situ hybridization analyses have previously demonstrated LRRK2 mRNA is at the highest levels in the cortex and striatum and we would expect significant quantities of LRRK2 protein in the temporal lobe [16,18,29-32]. Novus 267, Novus 268 and AP7099e all have sufficient specificity to detect human LRRK2 based on their ability to resolve a band of the predicted molecular weight of LRRK2 with identical solubility profiles (Figure 2B). Novus 268 and AP7099e are shown in comparison with our in-house antibody JH5514 (Figure 2B). Using gel systems other than Tris-Glycine such as Tris-Acetate or Bis-Tris gels causes a dramatically different migration of LRRK2 protein with respect to protein markers, with migration near 240 kDa in Tris-Acetate gels (data not shown).
###end p 22
###begin p 23
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Testing of LRRK2 antibodies on human tissue</bold>
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 150 155 <span type="species:ncbi:9606">human</span>
###xml 342 347 <span type="species:ncbi:9606">human</span>
Testing of LRRK2 antibodies on human tissue. A) Antibodies able to detect over-expressed human LRRK2 protein. B) Fresh frozen tissue samples from the human temporal lobe (Htl) is subjected to different extraction buffers as in figure legend 1A. Novus 267, Novus 268, Abgent AP7099e and JH5514 have sufficient specificity to detect endogenous human LRRK2. All antibodies were tested on at least two independent membranes and lysates using optimized exposure conditions with similar results.
###end p 23
###begin p 24
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 508 513 <span type="species:ncbi:9606">human</span>
We visualized LRRK2 protein by Western blot in human brain lysates derived from tissue with minimal delay in processing (fresh frozen brain samples) and have been unsuccessful in detecting LRRK2 protein from the vast majority of archived frozen brain samples that correspond to typical post-mortem delays (4-24 hours) (data not shown). This may be due to a high rate of degradation or processes that otherwise render LRRK2 inaccessible to detection by immunoblotting due to typical post-mortem delay in most human tissue samples available. We have not observed significant decay in LRRK2 protein within protein lysate when stored at -20 or -80 degrees or dramatic loss of LRRK2 due to freeze/thaw cycles (data not shown).
###end p 24
###begin title 25
LRRK1 and LRRK2 expression in development and adulthood
###end title 25
###begin p 26
###xml 127 132 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK </italic>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 220 224 220 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK</italic>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 407 412 407 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK </italic>
###xml 511 517 511 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 617 623 617 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 646 652 646 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 656 662 656 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 721 726 721 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A, B</xref>
###xml 775 781 775 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 785 791 785 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 855 857 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 860 866 860 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 924 930 924 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 36 46 <span type="species:ncbi:7227">Drosophila</span>
###xml 95 104 <span type="species:ncbi:7955">Zebrafish</span>
###xml 555 561 <span type="species:ncbi:9606">humans</span>
###xml 708 712 <span type="species:ncbi:10090">mice</span>
Many invertebrate organisms such as Drosophila and lower vertebrate organisms such as Fugu and Zebrafish possess only a single LRRK gene, suggesting mammalian LRRK1 and LRRK2 protein diverged from a single founder [33]. LRRK-like proteins and orthologues extend well beyond complex invertebrates into even simple single-celled eukaryotic organisms [34], suggesting a fundamental albeit unknown role for the LRRK family of proteins in mammals. Northern blot analysis has previously shown a broad distribution of LRRK2 mRNA in the brain and other organs in humans [1,2]. In order to better understand the regulation of LRRK2 expression we measured LRRK1 and LRRK2 mRNA in multiple organs in neonatal and adult mice (Figure 3A, B). We observed statistically identical levels of LRRK1 and LRRK2 mRNA in the lung, heart, skeletal muscle and lymph node (Figure 3B). LRRK2 mRNA is more abundant in kidney and brain tissue, whereas LRRK1 mRNA is more abundant in the gut.
###end p 26
###begin p 27
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 and LRRK2 mRNA levels in development and adulthood</bold>
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK </italic>
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP </italic>
###xml 164 184 164 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATA binding protein</italic>
###xml 306 311 306 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 439 445 439 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 449 455 449 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 507 510 507 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP</italic>
###xml 564 569 564 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
###xml 476 481 <span type="species:ncbi:10090">mouse</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
LRRK1 and LRRK2 mRNA levels in development and adulthood. A) Neonatal LRRK1 and LRRK2 mRNA levels. Relative LRRK expression was calculated by normalization to TBP (TATA binding protein) within each tissue sample using the delta delta CT method. Similar results were obtained with internal normalization to GAPDH. Error bars represent standard error mean derived from two each independently analyzed male and female 14 day old CD-1 mice B) LRRK1 and LRRK2 mRNA levels in adult mouse tissues as normalized to TBP. Similar results were obtained with normalization to GAPDH. Error bars represent standard error mean independently derived from two each female and male 3 month old CD-1 mice.
###end p 27
###begin p 28
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A,B</xref>
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 584 590 584 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 594 600 594 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 694 700 694 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 705 710 705 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 712 718 712 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 875 881 875 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 1071 1073 1071 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 1076 1082 1076 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 1181 1187 1181 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 1253 1259 1253 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 1385 1391 1385 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 1395 1401 1395 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 22 27 <span type="species:ncbi:10090">mouse</span>
###xml 233 238 <span type="species:ncbi:10090">mouse</span>
###xml 469 474 <span type="species:ncbi:10090">mouse</span>
Using Northern (whole mouse embryo) and Western (whole brain lysate) blotting we show that LRRK2 does not have an expression profile typical of a gene important during early development (Figure 4A,B). mRNA levels measured from whole mouse embryos show that LRRK2 expression increases from embryonic day 15 to day 17 (Figure 4A). Given the large increase in expression of LRRK2 during the latest stages of development, we created a panel of cDNA derived from developing mouse organs, including brain, lung, heart and liver, at various stages of development. We then went on to compare LRRK1 and LRRK2 levels using quantitative RT-PCR and observed a dynamic expression profile that distinguishes LRRK1 from LRRK2. LRRK2 most dramatically increases in lung and kidney between E15.5 and E19.5 partially accounting for the results of the whole-embryo Northern blot. Surprisingly, LRRK2 mRNA is constitutively expressed early in development of the brain and does not substantially increase upon cell maturation as might be expected by the Northern blot of whole embryo (Figure 4C). LRRK1 levels spike at E15.5 in the brain then decrease below LRRK2 levels and remain low with respect to LRRK2 throughout adulthood. In other organs such as the lung and liver, LRRK2 dramatically increases in the latest stages of development in contrast to the more constitutive expression in the heart where LRRK1 and LRRK2 are nearly identically expressed both in development and throughout adulthood.
###end p 28
###begin p 29
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 and LRRK2 mRNA levels in development and adulthood</bold>
###xml 143 149 143 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 292 298 292 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 302 308 302 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 463 467 463 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP </italic>
###xml 121 126 <span type="species:ncbi:10090">mouse</span>
LRRK1 and LRRK2 mRNA levels in development and adulthood. A) Northern blot analysis of different embryonic stages (whole mouse embryo) using a LRRK2 specific riboprobe. B) LRRK2 protein can be detected by JH5514 in whole brain lysates on E17 and throughout post-natal development C) Relative LRRK1 and LRRK2 mRNA levels in direct comparison calculated from whole brain, lung, heart and liver during embryonic stages E11.5 to E19.5, with internal normalization to TBP transcript. Error bars represent standard error mean independently derived from a total of four CD-1 embryos at the indicated age.
###end p 29
###begin title 30
Discussion
###end title 30
###begin p 31
###xml 283 289 283 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 643 648 643 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2</italic>
###xml 472 477 <span type="species:ncbi:9606">human</span>
###xml 562 567 <span type="species:ncbi:10090">mouse</span>
###xml 654 658 <span type="species:ncbi:10090">mice</span>
###xml 836 841 <span type="species:ncbi:9606">human</span>
###xml 1087 1092 <span type="species:ncbi:10090">mouse</span>
###xml 1145 1150 <span type="species:ncbi:10090">mouse</span>
###xml 1174 1179 <span type="species:ncbi:10090">mouse</span>
The function of LRRK proteins in mammals remains enigmatic yet strong evolutionary conservation suggests important roles. Besides obvious interest in understanding the only proteins in the mammalian proteome encoding both a kinase and GTPase domain, the striking association between LRRK2 and PD further justifies the speedy discovery of LRRK2 protein function in cells. Within the present study we show that several commercially available antibodies recognize endogenous human LRRK2 protein but no tested commercially available antibody can efficiently resolve mouse LRRK2 protein despite a number of reports that did not have the benefit of LRRK2-null mice. To the contrary, more abundant cross-reactive species near or at the molecular weight of mLRRK2 protein are detected by most commercially available antibodies as shown for the human specific Novus antibodies and the Abgent antibody AP7099b. Cross-reactive species likely mask endogenous mLRRK2 protein in the case of antibodies from Cell Signaling and Chemicon. However, both antibodies are capable of detecting over-expressed mouse protein. The Alexis antibody detects over-expressed mouse protein and endogenous mouse protein that migrates slightly below cross-reactive species. It may be possible with additional purification steps, blocking optimization, extraction optimization and improved washing and blotting conditions that some of the antibodies tested here will prove useful in the future.
###end p 31
###begin p 32
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 102 123 102 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATA binding protein </italic>
###xml 124 127 124 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP</italic>
###xml 133 146 133 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclophilin-A</italic>
###xml 178 184 178 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
In all tissues, LRRK1 and LRRK2 mRNA is rare compared to even nominally expressed transcripts such as TATA binding protein (TBP) and cyclophilin-A, both used here in addition to GAPDH as normalization controls. The combination of a poorly expressed transcript with an apparently unstable protein of above-average size creates a worst case scenario for routine detection of endogenous protein by Western blotting and immunocytochemistry despite the high solubility of LRRK2 protein.
###end p 32
###begin p 33
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 99 105 99 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 273 279 273 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 528 534 528 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 538 544 538 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 768 774 768 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 23 28 <span type="species:ncbi:10090">mouse</span>
###xml 133 138 <span type="species:ncbi:10090">mouse</span>
###xml 140 145 <span type="species:ncbi:10090">Mouse</span>
We describe cloning of mouse LRRK2 into expression vectors and the expression profile of LRRK1 and LRRK2 in the developing and adult mouse. Mouse LRRK2 expression increases from embryonic day 15 to day 17 and continues through adulthood. In some organs, such as the brain, LRRK2 expression apparently increases to a more nominal extent at earlier time points. We have been unable to detect LRRK2 protein in the brain before embryonic day 17 using the western blotting conditions and protein extraction protocols described here. LRRK1 and LRRK2 expression overlaps in all tissues used in this study (whole brain, eye, lung, skeletal muscle, smooth muscle, thymus, lymph node, heart, stomach, liver, kidney and gut), and in some tissues expression levels are identical. LRRK2 expression levels are particularly high in embryonic and adult lung and kidney. As kinase enzymes, LRRK protein may target tissue specific substrates for phosphorylation. It is possible that LRRK protein is so critical to cell function that the protein has diverged into two related proteins to provide a protective measure of redundancy in function.
###end p 33
###begin title 34
Conclusion
###end title 34
###begin p 35
###xml 95 101 95 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 350 356 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 458 464 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 468 474 468 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 248 253 <span type="species:ncbi:10090">mouse</span>
###xml 258 263 <span type="species:ncbi:9606">human</span>
###xml 360 365 <span type="species:ncbi:10090">mouse</span>
###xml 388 392 <span type="species:ncbi:10090">mice</span>
Knowledge about localization, function and substrates of LRRK1 and 2 protein will help clarify LRRK2 associated disease. We characterized twenty-one commercially available antibodies against LRRK2 protein and describe the biochemical properties of mouse and human LRRK2 proteins with regards to solubility and expression. The importance of LRRK1 and LRRK2 for mouse development and adult mice in different tissues is actively pursed by many research groups. LRRK1 and LRRK2 are comparably expressed in most tissues with stable expression in adulthood but dynamic expression during development, with a general trend towards increased expression during organogenesis and maturation.
###end p 35
###begin title 36
Methods
###end title 36
###begin title 37
Antibody production and western blotting
###end title 37
###begin p 38
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 323 329 323 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 972 978 966 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 1053 1059 1047 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 1176 1182 1170 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 18 24 <span type="species:ncbi:9986">rabbit</span>
###xml 137 142 <span type="species:ncbi:10090">mouse</span>
###xml 184 189 <span type="species:ncbi:9606">human</span>
###xml 335 340 <span type="species:ncbi:9606">Human</span>
###xml 375 380 <span type="species:ncbi:9606">human</span>
###xml 513 518 <span type="species:ncbi:10090">mouse</span>
###xml 537 542 <span type="species:ncbi:9606">human</span>
###xml 987 991 <span type="species:ncbi:10090">mice</span>
###xml 1047 1052 <span type="species:ncbi:10090">mouse</span>
###xml 1182 1186 <span type="species:ncbi:10090">mice</span>
###xml 1253 1257 <span type="species:ncbi:10090">mice</span>
###xml 1281 1286 <span type="species:ncbi:10090">mouse</span>
###xml 1328 1333 <span type="species:ncbi:9606">human</span>
Affinity-purified rabbit polyclonal antibodies were generated to LRRK2 protein as described previously [17]. Protein extracts from adult mouse and fresh frozen tissue samples from the human temporal lobe were prepared as described [17] and Western blot analysis (6% SDS-PAGE gels) was conducted as previously described for LRRK2 [19]. Human tissue samples were obtained from human brain temporal lobe resections snap-frozen immediately after removal and stored at -80degreesC until homogenization. Briefly: whole mouse brain or temporal human brain was mechanically homogenized in either PBS (low salt buffer), high salt buffer (PBS supplemented to 600 mM NaCl), 1% Triton X-100 (in PBS), 1% SDS (in PBS) or RIPA (1% SDS, 1% sodium deoxycholate, 1% NP-40). All buffers contained complete protease inhibitors (Roche). Antibodies were diluted 1:1000 in TBS-T containing 5% skimmed milk if not otherwise indicated. Incubation with primary antibodies was performed overnight. LRRK2 knockout mice were generated by disruption of exons 39 and 40 of the mouse LRRK2 gene (S. Biskup, M. Sasaki, V.L. Dawson and T.M. Dawson, personal observation). Wild-type, heterozygote and knockout LRRK2 mice were generated by crossbreeding of germline chimaeras to C57BL/6J mice. Protein extracts from mouse and fresh frozen tissue samples from the human temporal lobe were processed for Western blotting with LRRK2 antibodies as described above. LRRK2 antibodies were obtained from Abgent, Novus Biologicals, Abcam, Chemicon, Alexis and Cell Signaling.
###end p 38
###begin title 39
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 24 29 <span type="species:ncbi:10090">mouse</span>
Generation of human and mouse LRRK2 constructs
###end title 39
###begin p 40
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 18 23 <span type="species:ncbi:9606">human</span>
The generation of human LRRK2 constructs has been previously described [19,35].
###end p 40
###begin p 41
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 156 162 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 194 203 194 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PfuTurbo </italic>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 466 469 466 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kpn</italic>
###xml 471 474 471 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Not</italic>
###xml 631 637 631 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 662 668 662 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 751 757 751 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 758 761 758 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nde</italic>
###xml 763 766 763 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Not</italic>
###xml 803 809 803 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 24 29 <span type="species:ncbi:10090">mouse</span>
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
###xml 150 155 <span type="species:ncbi:10090">mouse</span>
The full-length cDNA of mouse LRRK2 was amplified from a Marathon-Ready mouse embryo 17d cDNA library (BD Biosciences). Using nested primers based on mouse LRRK2 (GenBank accession number ) and PfuTurbo hotstart DNA polymerase (Stratagene) according to the manufacturer's protocol, two overlapping fragments from exons 1-28 (~3.9 kb) and exons 15-51 (~5.9 kb) were generated. The first part of the LRRK2 cDNA (exons 1-28) was cloned in pBluescript SK+ (Stratagene) (KpnI/NotI) and sequenced with an ABI Prism Big Dye Terminator cycle sequencing kit on an ABI Prism 3730 DNA analyzer (Applied Biosystems). To generate a full-length LRRK2 clone the second part of LRRK2 (exons 15-51) was cloned in the pBluescript plasmid already containing one part of LRRK2 (NdeI/NotI). The entire open reading frame of LRRK2 (7584 bp) was confirmed by sequencing.
###end p 41
###begin title 42
Northern blotting
###end title 42
###begin p 43
###xml 531 537 519 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 589 595 577 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 6 11 <span type="species:ncbi:10090">mouse</span>
Whole mouse embryonic membranes were purchased from Clontech. Membranes were hybridized overnight at 65degreesC with a biotinylated antisense riboprobe synthesized using the MAXIscript in vitro transcription kit (Ambion) from a PCR-amplified DNA template with incorporated T7 promoter, and washed with 2 x SSC/1% SDS and then 0.1 x SSC/0.1% SDS at 65degreesC. Filters were visualized by incubation with streptavidin-alkaline phosphatase and chemiluminescence using the BrightStar BioDetect kit (Ambion). The riboprobe sequence for LRRK2 corresponds to nucleotide positions 4292 to 4813 of LRRK2 cDNA. PCR primers used were: forward 5'-TGAAGCCTTGGCTCTTCAAT-3' and reverse 5'-TAATACGACTCACTATAGGTACAAAGCCACTTGGGTTCC-3' with bold nucleotides representing the T7 promoter priming site.
###end p 43
###begin title 44
Quantitative reverse-transcription PCR
###end title 44
###begin p 45
###xml 685 691 685 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK1 </italic>
###xml 695 701 695 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 780 794 780 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclophilin A </italic>
###xml 814 820 814 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
RNA was isolated from embryonic and adult CD-1 mice (Charles Rivers) via mechanical homogenization and extraction in TriZOL and both cleaned and concentrated using a commercially available kit (Qiagen RNEasy Micro; Qiagen). Reverse transcription was performed using the Applied Biosystems High Capacity cDNA Reverse Transcription Kit (Applied Biosystems); cDNA concentrations were determined with a Nanodrop spectrophotometer (Nanodrop Technologies) prior to PCR. cDNA samples underwent absolute quantitative real-time PCR on the 9700HT instrument (Applied Biosystems) under the default 40-cycle program. TaqMan gene expression assays were purchased from Applied Biosystems, including LRRK1 and LRRK2 expression assays (assay Mm0481934 and Mm00713303), TBP (assay Mm00446973_m1), cyclophilin A (Mm02342429_g1) and GAPDH (4352932E). For each amplicon, PCR efficiency was estimated near 1.0 by serial dilutions of cDNA. Relative quantities of mRNA were estimated using the delta delta CT method.
###end p 45
###begin title 46
List of abbreviations
###end title 46
###begin p 47
###xml 135 140 <span type="species:ncbi:9606">human</span>
###xml 604 609 <span type="species:ncbi:9606">human</span>
leucine-rich repeat kinase 2 (LRRK2), leucine-rich repeat kinase 1 (LRRK1), Parkinson's Disease (PD), polymerase chain reaction (PCR), human embryonic kidney cells (HEK cells), pheochromocytoma cells (PC12 cells), phosphate buffered saline (PBS), sodium dodecyle sulfate (SDS), SDS polyacrylamide gel electrophoresis (SDS-PAGE), formic acid (FA), real time PCR (RT-PCR), embryonic day (E), postnatal day (P), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), TATA binding protein (TBP), sodium chloride/sodium citrate (SSC), Radioimmunoprecipitation (RIPA), sodium chloride (NaCl), Nonidet P-40 (NP-40), human temporal lobe (Htl), wild-type (WT), knock-out (KO).
###end p 47
###begin title 48
Authors' contributions
###end title 48
###begin p 49
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LRRK2 </italic>
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
SB, ABW, AR and CC carried out all experiments, BLD generated the mouse LRRK2 clone, DJM developed and purified the JH5514 antibody. TMD and VLD provided reagent and infrastructure support for the experiments and critically reviewed the manuscript. All authors read and approved the final manuscript.
###end p 49
###begin title 50
Acknowledgements
###end title 50
###begin p 51
###xml 442 447 <span type="species:ncbi:9606">human</span>
Supported by grants from the NIH, NINDS NS 38377, the Lee Martin Trust, the Sylvia Nachlas Trust, the National Parkinson Foundation and the American Parkinson Disease Association. T.M.D. is the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases. S.B. is supported by the German Research Foundation (Deutsche Forschungsgemeinschaft). A.B.W. is supported by a NIH/NINDS R00 NS058111. We would like to thank Dr. Laura Marsh for human brain tissue used in this study.
###end p 51
###begin article-title 52
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology
###end article-title 52
###begin article-title 53
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
###end article-title 53
###begin article-title 54
Genetics of Parkinson's disease and parkinsonism
###end article-title 54
###begin article-title 55
Molecular pathophysiology of Parkinson's disease
###end article-title 55
###begin article-title 56
Genetics of Parkinson's disease
###end article-title 56
###begin article-title 57
Genetics of Parkinson's disease
###end article-title 57
###begin article-title 58
A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease
###end article-title 58
###begin article-title 59
A common LRRK2 mutation in idiopathic Parkinson's disease
###end article-title 59
###begin article-title 60
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations
###end article-title 60
###begin article-title 61
G2019S LRRK2 mutation in French and North African families with Parkinson's disease
###end article-title 61
###begin article-title 62
LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews
###end article-title 62
###begin article-title 63
Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease
###end article-title 63
###begin article-title 64
Deciphering the role of heterozygous mutations in genes associated with parkinsonism
###end article-title 64
###begin article-title 65
Lrrk2 and Lewy body disease
###end article-title 65
###begin article-title 66
Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation
###end article-title 66
###begin article-title 67
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain
###end article-title 67
###begin article-title 68
Localization of LRRK2 to membranous and vesicular structures in mammalian brain
###end article-title 68
###begin article-title 69
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain
###end article-title 69
###begin article-title 70
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
###end article-title 70
###begin article-title 71
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity
###end article-title 71
###begin article-title 72
Biochemical and pathological characterization of Lrrk2
###end article-title 72
###begin article-title 73
LRRK2 protein is a component of Lewy bodies
###end article-title 73
###begin article-title 74
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 61 66 <span type="species:ncbi:9606">human</span>
LRRK2 expression in normal and pathologic human brain and in human cell lines
###end article-title 74
###begin article-title 75
The familial Parkinsonism gene LRRK2 regulates neurite process morphology
###end article-title 75
###begin article-title 76
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
###end article-title 76
###begin article-title 77
Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1
###end article-title 77
###begin article-title 78
Leucine-rich repeat kinase 2 associates with lipid rafts
###end article-title 78
###begin article-title 79
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease
###end article-title 79
###begin article-title 80
###xml 80 85 <span type="species:ncbi:9606">human</span>
Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain
###end article-title 80
###begin article-title 81
LRRK2 expression linked to dopamine-innervated areas
###end article-title 81
###begin article-title 82
###xml 59 64 <span type="species:ncbi:10090">mouse</span>
Anatomical localization of leucine-rich repeat kinase 2 in mouse brain
###end article-title 82
###begin article-title 83
###xml 35 38 <span type="species:ncbi:10116">rat</span>
###xml 43 48 <span type="species:ncbi:10090">mouse</span>
Distribution of PINK1 and LRRK2 in rat and mouse brain
###end article-title 83
###begin article-title 84
The Parkinson disease gene LRRK2: evolutionary and structural insights
###end article-title 84
###begin article-title 85
Roc, a Ras/GTPase domain in complex proteins
###end article-title 85
###begin article-title 86
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity
###end article-title 86

